Medicare Expands Coverage of Popular Weight-Loss Drug Wegovy for Heart Health

• Medicare plans can now cover Wegovy for patients with a history of cardiovascular disease, expanding access to the popular weight-loss drug.

• The policy change comes after the FDA approved Wegovy to reduce the risk of heart failure in overweight adults.

• Medicare Part D plans can cover Wegovy for heart benefits, but generally not for weight loss alone.

• The move could pressure commercial insurers to also cover Wegovy, an expensive but high-demand drug.

• Covering Wegovy for just 10% of Medicare beneficiaries would cost $13.6 billion, raising affordability questions.